Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613158 · ClinicalTrials.gov registry record
Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk
A clinical trial of Cardiovascular Diseases and Atherosclerosis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT00613158: Completed study of Cardiovascular Diseases and Atherosclerosis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00613158 is a study of Cardiovascular Diseases and Atherosclerosis that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 120 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00613158, a study of Cardiovascular Diseases and Atherosclerosis, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Cardiovascular disease (CVD), including heart disease, heart attack, high blood pressure, and stroke, is most commonly caused by atherosclerosis, or a hardening of the arteries. Traditional risk factors for CVD include age, high blood pressure, high cholesterol, diabetes, and smoking. Although these established risk factors can be helpful in determining people at risk for developing CVD, the addition of novel gene markers for subclinical, or suspected, atherosclerosis (SA) may enhance CVD risk prediction and understanding of disease mechanisms. This study will compare specific genes of white blood cells in people with significant SA versus people without SA to improve identification of those at risk for developing CVD and to better understand the biological basis of SA.
Conditions Studied
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-02 |
What the finished NCT00613158 record still lists
NCT00613158 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT00613158 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00613158 about?
NCT00613158 is a clinical study titled "Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk". Cardiovascular disease (CVD), including heart disease, heart attack, high blood pressure, and stroke, is most commonly caused by atherosclerosis, or a hardening of the arteries. Traditional risk factors for CVD include age, high blood pressure, high cholesterol, diabetes, and smoking. Although these...
What is the current status of trial NCT00613158?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2007-03. Estimated completion is 2010-02.
What conditions does trial NCT00613158 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Atherosclerosis.
Who is sponsoring clinical trial NCT00613158?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00613158 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00613158's enrollment target sits among peer trials
120 181st of 300 higher than 116 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
RECRUITING
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia